Cigna Strongly Beats On Q2 Earnings; Raises FY21 Sales Outlook, Expects Higher Unfavorable COVID-19 Impact

  • Cigna Corp CI reports Q2 total revenues of $43.1 billion, +9.8% Y/Y, ahead of the consensus of $41.31 billion.
  • Q2 adjusted EPS reached $5.24 compared with $5.81 a year ago, beating the consensus of $4.96. 
  • The pharmacy customer base grew to 101.9 million, up 5% Y/Y, and an organic increase of 3.1 million YTD. The total medical customer base reached 16.9 million, increasing 279,000 customers YTD, down marginally by 0.3% Y/Y.
  • Evernorth adjusted revenues increased 17% Y/Y $32.6 billion driven by growth in retail network and specialty pharmacy services, offset by lower retail script volumes due to the COVID-19 pandemic.
  • Evernorth fulfilled 410 million pharmacy scripts, +13% Y/Y led by organic growth and COVID-19 vaccines.
  • U.S. Medical adjusted revenues grew 13% to $10.5 billion.
  • The debt-to-capitalization ratio was 40.5%, in line with the long-term target of approximately 40%.
  • The SG&A expense ratio was 6.9%, a decrease from 8.4% from Q2 2020.
  • Guidance: Cigna expects FY21 sales of at least $170 billion ($166 billion previously).
  • It reaffirms adjusted EPS guidance of at least $20.20 versus the consensus of $20.42. This outlook includes approximately $2.50 per share ($1.25 previously) in net unfavorable impacts of COVID-19.
  • Price Action: CI shares closed at $231.48 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!